The role of the KIT protooncogene in human hematopoiesis is uncertain. Therefore, we examined KIT mRNA expression in normal human bone marrow mononuclear cells (MNC) and used antisense oligodeoxynucleotides (oligomers) to disrupt KIT function. KIT mRNA was detected with certainty only in growth factor-stimulated MNC. Expression was essentially abrogated by making MNC quiescent or by inhibiting myb gene function. Oligomers blocked KIT mRNA expression in a dos-response and sequence-specific manner, thereby allowing functional examination of the KIT receptor. In experiments with either partially purified or CD34+-enriched MNC, neither granulocyte nor megakaryocyte colony formation was inhibited by oligomer exposure. In contrast, KIT antisense oligomers inhibited interleukin 3/erythropoietin-driven erythroid colony formation -70% and "stem cell factor"/erythropoietin-driven colony formation 100%. The
expression in a dos-response and sequence-specific manner, thereby allowing functional examination of the KIT receptor. In experiments with either partially purified or CD34+-enriched MNC, neither granulocyte nor megakaryocyte colony formation was inhibited by oligomer exposure. In contrast, KIT antisense oligomers inhibited interleukin 3/erythropoietin-driven erythroid colony formation -70% and "stem cell factor"/erythropoietin-driven colony formation 100%. The presence of erythroid progenitor cell subsets with differential requirements for KIT function is therefore suggested. Growth of hematopoietic colonies from chronic myeloid leukemia and polycythemia vera patients was also inhibited, while acute leukemia colony growth appeared less sensitive to KIT deprivation. These results suggest that KIT plays a predominant role in normal erythropoiesis but may be important in regulating some types of malignant hematopoietic cell growth as well.
They also suggest that KIT expression is linked to cell metabolic activity and that its expression may be regulated by or coregulated with MYB.
The c-kit protooncogene is the normal cellular homologue of v-kit, the Hardy-Zuckerman 4 feline sarcoma virus oncogene (1) . c-kit encodes a dimeric transmembrane tyrosine kinase receptor homologous to the colony-stimulating factor 1 and platelet-derived growth factor receptors (2) . The mouse c-kit gene, Kit, has been mapped to chromosome 5, where it was determined to be allelic with the dominant white spotting locus (W) (3) . W mice have a variety of abnormalities affecting coat color, gonadal development, and hematopoiesis. The latter is characterized by a marked reduction in the number of erythroid burst-forming units (BFU-E) (4) and a profound macrocytic anemia (5) . The molecular lesions responsible for these defects are now being defined (6, 7) .
The ligand for Kit has also recently been identified (reviewed in ref. 8 ). The encoded protein, known as stem cell factor (SCF), mast cell growth factor (MGF), or steel factor (SLF) is the product of a gene that resides at the steel (SI) locus. Mice with SI mutations have phenotypic abnormalities quite similar to those of W mice, and the explanation for this curiosity is now apparent. The W mouse lacks or has defects in a critical signal transducing receptor encoded by Kit, while the SI mouse has defects in the ligand that stimulates the Kit receptor.
The above observations establish the critical importance of the Kit receptor in murine hematopoietic stem cell development, but its importance in human hematopoiesis remains unclear, since human mutations at the corresponding locus, KIT, on chromosome 4 have not been described. Therefore, to examine the role of the KIT receptor in human hematopoiesis, we examined KIT mRNA expression in normal human bone marrow mononuclear cells (MNC) and used antisense oligodeoxynucleotides (oligomers) to abrogate KIT function. Our results suggest that KIT plays a predominant role in normal erythropoiesis and that it might be of importance in regulating some types of malignant hematopoietic cell growth.
MATERIALS AND METHODS
Cells. Normal light-density MNC were obtained from consenting normal human donors and depleted of adherent cells and T lymphocytes (A-T-MNC) as described (9) . In some experiments, CD34' cells were enriched from the A-T-MNC population by immunoselection with magnetic beads (Dynal, Oslo).
Malignant human hematopoietic cells were isolated by using the above techniques from the bone marrow or peripheral blood of patients with acute myelogenous leukemia (AML), acute lymphatic leukemia (ALL), Philadelphia chromosome-positive chronic myelogenous leukemia (CML), or polycythemia vera (PV).
Oligodeoxynucleotides. Unmodified, 18-nucleotide oligomers were synthesized and purified as reported (9) (10) (11) (12) (13) (14) . Oligomers were lyophilized to dryness and redissolved in culture medium prior to use [1 jug/,lt (0.175 ,uM)]. Oligomer sequences used, corresponding to codons 1-6 of the published human KIT cDNA sequence (2), were as follows: 5'-ATG AGA GGC GCT CGC GGC-3' sense oligomer, 5'-GCC GCG AGC GCC TCT CAT-3' antisense oligomer, and 5'-GCA CCG TCT GCC AGT CGC-3' scrambledsequence oligomer.
Oligomer Exposure and Cell Culture. Cells were exposed to oligomers as described (14) . A-T-MNC (2 x 105) or CD34' MNC (2 x 104) were incubated in 0. 4 AB serum and 10 mM Hepes buffer in polypropylene tubes (Fisher Scientific). Oligomers (2.5-100 gg/ml) were added at time zero, and 50% of the initial dose was added again 18 hr later (final total concentration, -0.6-26 1LM). Twenty-four hours after the first addition of oligomers, cells were prepared for plating in plasma clot or methylceliulose cultures as reported (9, 13, 14) . Cells (1 x 10 A-T-MNC or 1 x 104 CD34' MNC per dish) were not washed before plating.
Control cultures were manipulated in an identical manner but did not contain oligomers.
Assays for hematopoietic progenitor cells of various lineages were carried out as reported (9, 13, 14) . Erythroid colony-forming units (CFU-E) were stimulated with erythropoietin (EPO; 5 units/ml); BFU-E, with EPO and interleukin 3 (IL-3; 20 units/ml) or EPO and SCF (100 ng/ml); granulocyte/macrophage colony-forming units (CFU-GM), with IL-3 (20 units/ml) and granulocyte/macrophage colonystimulating activity (5 ng/ml)]; and megakaryocyte colonyforming units (CFU-MEG), with IL-3 (20 units/ml) and IL-6 (100 ng/ml). Colony identification was carried out as described (9, 13, 14) .
Reverse-Transcription Polymerase Chain Reaction (RT-PCR). Total RNA was extracted from cells (2-5 x 106) as reported (14) . RNA was reverse-transcribed with 500 units of Moloney murine leukemia virus reverse transcriptase (Mo-MLV-RT) and 50 pmol of a 22-nucleotide 3' primer complementary to nucleotides 1201-1179 [CTA GGA ATG TGT AAG TGC CTC C] of the published KIT cDNA sequence (2) . The resulting cDNA fragment was amplified by using 5 units of Thermus aquaticus (Taq) polymerase and a 22-nucleotide 5' primer specific for nucleotides 842-864 [CGT TGA CTA TCA GTT CAG CGA G]. Twenty-five microliters of amplified product was electrophoresed on 4% agarose gel and subsequently transferred to a nylon filter. Filters were prehybridized and then probed with a 32P-end-labeled oligonucleotide probe corresponding to a 21-nucleotide KIT sequence [GAT CCA CTG CTG GTG TTC AGG] contained within the amplified region (nucleotides 1068-1047). Autoradiography was performed by exposing filters on Kodak x-ray film at -70°C with intensifying screens.
Statistical Analysis. Statistical significance of differences in numbers of colonies arising in the duplicate control, sense, or antisense plates was determined by using the Student t test for unpaired samples. P values less than 0.05 were judged to be of statistical significance. RESULTS
Expression of KIT mRNA in Normal MNC. We first sought to determine (i) if expression of KIT mRNA was detectable in MNC, (ii) the relationship between KIT gene expression and cellular metabolic activity, and (iii) if KIT mRNA expression varied with time in culture. To carry out these studies, A-T-MNC were placed in tissue culture medium containing 2% normal human AB serum at 4°C. Twenty-four hours later, the cells were rapidly warmed to 37°C, the culture medium serum concentration was adjusted to 5% (vol/vol) and supplemented with 20 units of recombinant human IL-3 and 5 units of erythropoietin per ml. Immediately (time 0) and at 2-, 8-, 12-, 24-, 36-, and 48-hr intervals thereafter, RNA was extracted from cells for RT-PCR-based analysis of KIT expression ( Fig. 1 ). MNC at 4°C appeared to express KIT mRNA at extremely low levels, since a signal was detectable at time 0 only after prolonged exposure ofthe autoradiogram. Within 2 hr of stimulation, however, KIT expression was unequivocally detectable. It continued to increase through 24 hr, at which time expression appeared to peak and persisted through 48 hr. Though PCR is at best semiquantitative, the fact that equivalent results were obtained on three separate occasions suggests that these results are likely to reflect real-time kinetics. The results of these experiments suggested the possibility that KITexpression might also be linked to cell cycle activity. To explore this further, we examined the relationship between MYB expression, a critical regulator of G1/S transition (11), and KIT expression (Fig. 2) . MNC were exposed to MYB antisense oligomers and then cultured as described in the legend of Fig. 2 . We again found KIT mRNA to be weakly expressed immediately after rewarming from 40C ( Fig. 2 Upper, lane 1) but detectable in control and MYB senseoligomer-treated cells after 36 hr (370C in the presence of growth factors) (Fig. 2 Upper, lanes 2 and 3). In marked contrast, KIT mRNA was not detectable in cells exposed to the MYB antisense oligomers (Fig. 2 Upper, lane 4). Simultaneous assay for 3-actin message showed no significant change in mRNA levels, suggesting that the decrement in KIT expression was specifically related to down-regulation of MYB (Fig. 2 Lower) . These results suggest that in normal hematopoietic cells, KIT may be regulated by or coregulated with MYB.
Effect of KIT Oligomers on Normal Human Hematopoietic Progenitor Cell Growth. We then determined if KIT expression in MNC could be abrogated in a sequence-specific manner by exposure to KIT antisense oligodeoxynucleotides (Fig. 3) . A-T-MNC (2 x 106) were again incubated at 40C for 24 hr in a low serum (2%)-containing medium. Cells were rewarmed to 370C and exposed to growth factors as described above in the presence of KIT oligomers. After 36 hr, total RNA was extracted for RT-PCR detection of KIT message. KIT mRNA was expressed at a very low level after 24 hr at 4°C (Fig. 3) . Thirty six hours after warming, KIT mRNA was detected in control cells and in cells exposed to sense and placed at 4°C for 24 hr in 5 ml polypropylene tubes (Fisher Scientific) in a total volume of 0.4 ml of Iscove's modified Dulbecco's medium containing 2% human AB serum and 10 mM Hepes buffer. Cells were then rewarmed to 37°C in supplemented a medium containing 5% AB serum, IL-3 (20 units/ml) and EPO (5 units/ml). Oligomers were added at the time of rewarming (time 0; 80 ,g/ml), and 50% of the initial dose was added again 18 hr later. Thirty-six hours after the first addition of oligomers, total RNA was extracted for RT-PCR analysis of KIT expression (Upper) and P-actin expression (Lower) (10 Fig. 1 . Cells were exposed to oligomers as previously described (6) . A-T-MNC (2 x 106) were incubated as described in Fig. 1 scrambled-sequence oligomers. In contrast, antisensetreated cells had no detectable KIT mRNA. Accordingly, inhibition of KIT expression was highly efficient and sequence specific.
The effect of KIT antisense and control sequence oligomers on normal hematopoietic progenitor cell cloning efficiency and development was then systematically investigated by assessing the effect of oligomer exposure on CFU-E-, BFU-E-, CFU-GM-, and CFU-MEG-derived colony growth. KIT antisense oligomers inhibited erythroid colony formation in a dose-dependent fashion (Fig. 4) . Inhibition was sequence specific since neither sense nor scrambledsequence oligomers significantly affected colony growth in comparison with untreated controls. At the highest doses used, nonspecific inhibition of erythroid colony formation was sometimes seen (experiment 2 in Table 1 ), but this inhibition was never as great as that observed with the antisense oligomers. These inhibited growth of CFU-E and BFU-E -75% and =71%, respectively (Table 1) . Residual colonies were much smaller than those of the untreated controls (Fig. 5) . Nevertheless, maturation of the cellular constituents of the colonies appeared to be normal in terms of the cells' ability to synthesize hemoglobin (Fig. 5) Fig. 1 , oligomers were added at time 0 (2.5-100 ,ug/ml), and 50%o of the initial dose was added again 18 hr later (final total concentration 1-52.5 ,uM). Twenty-four hours after the first addition of oligomers, cells were prepared for plating in plasma clot or methylcellulose cultures (6, 7) . Cells were not washed before plating. Control cell cultures were untreated. Bars: 1, Untreated control cells; 2, Antisense treatment of 20 pzg/ml followed by 10 iLg/ml; 3, antisense treatment of 40 ,ug/ml followed by 20 tzg/ml; 4, antisense treatment of 100 ,ug/ml followed by 50 u&g/ml; 5, sense treatment of 100 ,ug/ml followed by 50,ug/ml; 6, scrambled-sequence treatment of 100 ,ug/ml followed by 50 ,ug/ml. formation was unaffected by exposure to any ofthe oligomers at any of the doses used (Table 1) .
Similar results were obtained after exposure ofCD34' cells to KIT antisense oligomers. The mean number of BFU-E colonies decreased -71% (Table 2) . Neither sense nor scrambled-sequence oligomers significantly inhibited erythroid colony formation. As was also noted with the less pure A-Tpopulation, neither antisense nor control oligomers inhibited CFU-GM colony formation.
To provide additional proof that KIT antisense-mediated inhibition of erythropoiesis was due to the absence of KIT receptor function, we sought to demonstrate that BFU-E responsiveness to SCF could be abolished in a sequencespecific manner after exposure to KIT oligomers. Accordingly CD34' MNC (1 x 104) were cloned in the presence of 5 units of EPO and 100 ng of SCF per ml alone or with sense, antisense, or scrambled-sequence KIT oligomers [final concentration, 150 ,ug/ml (=26 ,tM)]. In four experiments, 191 ± 19 BFU-E (mean ± SD) were grown in the presence of the growth factors alone. These numbers were not statistically different from those cloned with sense (183 ± 29; P = 0.654) or scrambled-sequence oligomers (180 + 20; P = 0.758). In the presence of the kit antisense oligomers, BFU-E-derived colony formation was completely abolished (0.4 ± 0.7; P < 0.0001), suggesting that KIT receptor was no longer present to interact with its ligand.
Role of KIT Receptor in Malignant Hematopoietic Ceil Growth. The above data suggest that the KIT-encoded receptor plays an important role in normal hematopoiesis, especially for erythroid cell development. KIT mRNA and protein has been detected in some acute leukemias, suggesting a role for the KIT-encoded protein in malignant hematopoietic cell growth as well (15, 16) . Nevertheless, its importance in the pathogenesis of these diseases remains unclear, since expression in primary leukemias is quite variable (15, 16) and, to our knowledge, has not been examined in other malignant hematopoietic diseases such as the myeloproliferative disorders. To address this issue, A-T-MNC were obtained from patients with a variety of hematologic malignancies and were exposed to the KIT oligomers. The effect of oligomer exposure on the ability of malignant CFU-GM to form colonies in semisolid medium was then assessed (Table  3) . Twenty-one patients were studied: 3 with ALL, 4 with AML, 10 with CML, and 4 with PV. CFU-GM from 11 of these patients were inhibited by exposure to the KIT antisense oligomers. Of these, 9 were derived from patients with myeloproliferative disorders (all but one indeterminate case had PCR-documented expression of KIT mRNA; data not shown), suggesting that progenitor cells isolated from patients with these disorders were more dependent on KIT function than were those with acute leukemia. Five responding patients had CML. Interestingly, when residual colonies were probed for bcr-abl-expressing cells by RT-PCR (14, 17) , bcr-abl expression was substantially decreased or undetectable in cases where colony inhibition was observed. In patients with PV, both BFU-E-(92% + 3) and CFU-GMderived colony formation (Table 3) were significantly inhibited by the KIT antisense oligomers.
DISCUSSION
The importance of the KIT receptor in murine hematopoiesis is undisputed. Inferential data that the receptor plays a significant role in human hematopoiesis are also accumulating, primarily in the form of studies demonstrating that the KIT ligand stimulates the growth of hematopoietic colonies (8, 18) . The KIT ligand appears to have little colonystimulating activity on its own but instead acts synergistically with other growth factors, in particular with IL-3, to enhance colony formation. Nevertheless, because a certain amount of "cross talk" is known to exist among the hematopoietic growth factors, the importance of the KIT ligand's receptor in regulating hematopoietic cell development remains undefined. Similarly, the biological function(s) governed by the KIT receptor remain unspecified. Given its similarity to other growth factor receptors, it is likely a component of a growth factor signal-transduction apparatus. Other functions, such as serving as a cell surface adhesion molecule receptor, are also possible (19) .
Though the exact function of the receptor remains undefined, the data presented herein provide insight into factors that regulate KIT expression in normal human MNC. In this regard, we found (i) that expression of KIT was virtually undetectable in cells that had been rendered quiescent by exposure to cold and a low serum environment and (ii) that expression increased after cells were rewarmed and then stimulated with IL-3 and erythropoietin (Fig. 1) . Whether the augmented KIT expression we found was due to increased metabolic activity of the cell or was related to initiation of cell cycle activity remains to be determined. Nevertheless, since Fig. 2) , initial expression in G. cells would not appear to be dependent on the activation of "late" cell cycle genes such as MYB. The role of early genes, such as MYC, in triggering KIT expression needs exploration. However, since pertubation of MYB function led to downregulation of KITexpression at 36 hr without affectingf-actin mRNA expression, KIT may be regulated by different mechanisms in cells that are cycling and in a manner independent of cellular metabolic activity. These regulatory mechanisms also require elucidation but may be MYB-related, at least in normal cells.
These findings conflict with a recent report suggesting that KIT expression is unrelated to cellular metabolic activity or cell cycle state and that mRNA levels decline after cells are exposed to hematopoietic growth factors (20) . Different target cells may be one explanation for these discordant results. On the other hand, our data are consistent with the observation that KIT ligand synergizes with IL-3-stimulated cells in promoting erythroid colony growth (4). These widely observed results are difficult to reconcile with the observation that exposure to IL-3 might down-regulate KIT receptor mRNA and protein (20) .
In addition to elucidating biological factors that regulate KIT expression, the experimental approach used has also generated some unexpected findings about the importance of KIT expression in human hematopoietic cell development. First, the KIT receptor does not appear to play a critical role in either myeloid or megakaryocyte development, at least at the early progenitor cell level. This statement follows from the observation that cells of both lineages appear to develop normally after exposure to the antisense oligomers. Whether development from even earlier progenitor cells than those assayed or from cells with more "stem"-like properties would also be unaffected is unclear. In marked contrast to these results, however, erythroid colony development at both the BFU-E and CFU-E level appeared to be markedly dependent on KIT function. This dependence appeared to be most critical during the early events of colony formation, since maturation in residual colonies was otherwise normal.
Second, the results also strongly imply the existence of two distinct subsets of erythroid progenitors with different dependence on the KIT ligand, and therefore the KIT receptor.
These subsets may differ in their maturational state and other as yet unidentified properties.
Finally, the KIT receptor may be of importance in regulating growth of some malignant hematopoietic cell types as well. In this regard, it was found that growth of granulocyte colony-forming units from most cases of acute leukemia, either AML or ALL, was not inhibited by exposure to the KIT antisense oligomers. In contrast, growth of granulocyte colony-forming units derived from patients with CML and PV was much more sensitive to the inhibitory effects of the KIT antisense oligomers. The reason for this discrepancy is unclear. One possible explanation may be that CFU from patients with acute leukemia are blocked at a maturation level where KIT function is relatively unimportant for cell growth. This situation would contrast with CFU from patients with myeloproliferative disorders who are likely to have progenitor cells at varied levels of maturation. Alternatively, acute leukemia CFU may have generated alternate ways of carrying out KIT-related functions so that receptor deprivation does not adversely effect cell growth. Finally, the data suggest that KIT may subserve different functions in normal as opposed to malignant hematopoietic cells since CFU-GMderived granulocyte-macrophage colony formation was unaffected by KIT disruption in the former but led to inhibition of colony formation in the latter cell types. It is possible that these differences can be exploited for therapeutic purposes.
